Key Financials
List: Small Cap
Market Cap: 266 MSEK
Industry: Information Technology
CEO: Christian Sundin
Chairman: Bo Nordlander
7.0 points 4.0 points 6.0 points 6.0 points 4.0 points
Share information
Share price (SEK) 5.3
Number of shares (m) 50.1
Market Cap (MSEK) 266
Net debt (MSEK) 140
Free float (%) 80 %
Daily turnover (’000) 146
Analysts:
Alexander Sattelmaier [email protected]
Good quarter with reduced
profit due to focus on future
opportunities
Formpipe Software’s report for the third quarter of 2014 showed revenues slightly above our expectations. They were at 81.9 million SEK, however with a resulting net income of only 2 million SEK.
The weaker margins were mainly due to the ongoing build-up of the Swedish delivery organization and other costs related to future growth.
The third quarter results include those of recent acquisition of UK-based GXP Limited (“GXPi”), which underlines the company’s efforts to get a foothold in the competitive Life Science sector.
No updates to Redeye Rating
0 1 2 3 4 5 6 7 8
28-Oct 26-Jan 26-Apr 25-Jul 23-Oct
OMXS 30 Formpipe Software
Management Ownership Growth prospect Profitability Financial strength
Summary
Formpipe Software
(fpip.st)
Redeye Rating (0 – 10 points)
2012 2013 2014E 2015E 2016E
Revenue, MSEK 201 294 347 376 397 Growth 79% 46% 18% 8% 6% EBITDA 51 65 71 89 112 EBITDA margin 25% 22% 21% 24% 28% EBIT 29 27 30 45 60 EBIT margin 14% 9% 9% 12% 15% Pre-tax earnings 16 20 22 37 54 Net earnings 14 16 16 29 42 Net margin 7% 5% 5% 8% 11%
2012 2013 2014E 2015E 2016E
P/E adj. 0.0 17.7 16.3 9.3 6.4
EV/S 1.0 1.5 1.3 1.1 1.0
EV/EBITDA 3.8 6.7 6.3 4.8 3.5
2012 2013 2014E 2015E 2016E
Dividend/Share 0.00 0.00 0.07 0.11 0.17
Redeye Rating: Background and definitions
The aim of a Redeye Rating is to help investors identify high-quality companies with attractive valuation.
Company Qualities
The aim of Company Qualities is to provide a well-structured and clear profile of a company’s qualities (or operating risk) – its chances of surviving and its potential for achieving long-term stable profit growth.
We categorize a company’s qualities on a ten-point scale based on five valuation keys; 1 – Management, 2 – Ownership, 3 – Growth Outlook, 4 – Profitability and 5 – Financial Strength.
Each valuation key is assessed based a number of quantitative and qualitative key factors that are weighted differently according to how important they are deemed to be. Each key factor is allocated a number of points based on its rating. The assessment of each valuation key is based on the total number of points for these individual factors. The rating scale ranges from 0 to +10 points.
The overall rating for each valuation key is indicated by the size of the bar shown in the chart. The relative size of the bars therefore reflects the rating distribution between the different valuation keys.
Management
Our Management rating represents an assessment of the ability of the board of directors and management to manage the company in the best interests of the shareholders. A good board and management can make a mediocre business concept profitable, while a poor board and management can even lead a strong company into crisis. The factors used to assess a company’s management are: 1 – Execution, 2 – Capital allocation, 3 – Communication, 4 – Experience, 5 – Leadership and 6 – Integrity.
Ownership
Our Ownership rating represents an assessment of the ownership exercised for longer-term value creation. Owner commitment and expertise are key to a company’s stability and the board’s ability to take action. Companies with a dispersed ownership structure without a clear controlling shareholder have historically performed worse than the market index over time. The factors used to assess Ownership are: 1 – Ownership structure, 2 – Owner commitment, 3 – Institutional ownership, 4 – Abuse of power, 5 – Reputation, and 6 – Financial sustainability.
Growth Outlook
Our Growth Outlook rating represents an assessment of a company’s potential to achieve long-term stable profit growth. Over the long-term, the share price roughly mirrors the company’s earnings trend. A company that does not grow may be a good short-term investment, but is usually unwise in the long term. The factors used to assess Growth Outlook are: 1 – Strategies and business model, 2 – Sale potential, 3 – Market growth, 4 – Market position, and 5 – Competitiveness.
Profitability
Our Profitability rating represents an assessment of how effective a company has historically utilised its capital to generate profit. Companies cannot survive if they are not profitable. The assessment of how profitable a company has been is based on a number of key ratios and criteria over a period of up to the past five years: 1 – Return on total assets (ROA), 2 – Return on equity (ROE), 3 – Net profit margin, 4 – Free cash flow, and 5 – Operating profit margin or EBIT.
Financial Strength
Our Financial Strength rating represents an assessment of a company’s ability to pay in the short and long term. The core of a company’s financial strength is its balance sheet and cash flow. Even the greatest potential is of no benefit unless the balance sheet can cope with funding growth. The assessment of a company’s financial strength is based on a number of key ratios and criteria: 1 – Times-interest-coverage ratio, 2 – Debt-to-equity ratio, 3 – Quick ratio, 4 – Current ratio, 5 – Sales turnover, 6 – Capital needs, 7 – Cyclicality, and 8 – Forthcoming binary events.
Investing for future growth
Similar to the first quarter, Q3 has historically been a weaker quarter for Formpipe Software, which was also the case this year after adjusting for the effect of the GXPi acquisition. At the same time, the company’s sales have slightly beaten our expectations. After adjusting for the acquisition of British GXP Ltd. (GXPi) effective July 1st, we expected sales around 79 MSEK for the quarter, while Formpipe delivered 81.9 MSEK. This amounts to a 9.8% YoY growth excluding the revenue contribution from GXPi (16.5% including this effect).
Profitability has however been down, with Formpipe’s Q3 EBITDA-margin at 21.3% (26.9%), with both the EBITDA of 17.5 MSEK and net profit of 2 MSEK being below our expectations due to increased sales- and other operating expenses. We see this mainly as an effect of investments in areas of future growth as well as the use of subcontractors in the Danish
operations.
While support and maintenance revenue was according to our expectations, both license and delivery sales were slightly higher than we expected.
A major difference in the actuals compared to our estimates can be seen in sales and other costs.
Expected vs. Actual
(SEKm) Q3'13 Q3'14E Actual Diff
Sales 70,3 79,0 81,9 4%
EBITDA 18,9 20,0 16,8 -16%
EBIT 9,4 10,0 5,3 -47%
EPS 0,10 0,12 0,04 -66%
Sales growth YoY 24% 12% 16%
EBIT margin 13% 13% 6%
So urce: Redeye Research
Expected vs. Actual Revenues
(SEKm) Q3'14E Actual Diff
Support and maintenance 38,0 38,1 0%
License 12,0 13,0 8%
Delivery 29,0 30,8 6%
So urce: Redeye Research
Expected vs. Actual Costs
(SEKm) Q3'14E Actual Diff
Sales cost 8,5 13,2 56%
Other cost 14,0 15,4 10%
Personnel cost 44,1 44,7 1%
Activated development cost 8,0 8,9 11%
So urce: Redeye Research Formpipe’s Q3 revenues
slightly beat our
expectations, but margins were lower due to expansion activities
License and delivery sales were slightly above expectations, while sales costs were much higher
This is firstly due to investments Formpipe is making in growth areas. Besides costs resulting from the GXPi acquisition, the company is setting up operations in the US and Netherlands and in the ongoing process of
building up its delivery organization in Sweden.A second factor affecting profitability specifically in the Danish operations is that Formpipe uses subcontractors for the delivery of certain contracts. While this reduces the margins on these contracts, it helps to increase operational flexibility and better manage demand fluctuations.
Swedish market back to normal after elections, mixed picture in Denmark
The recent elections on both a European and national level have likely captured a big part of the focus of Swedish authorities. Now that this period is over, the planning and budget attention regarding IT solutions should be back to normal, which should be beneficial for Formpipe in the months going forward.
The municipality market in Denmark on the other hand still remains somewhat of a challenging environment to be in, with only one contract closed in 2014. Formpipe has however constantly signed contracts with other segments in the Danish public sector, reinforcing their positioning as a provider of choice in the overall market. An additional option for
accelerated growth in this area could be increased upselling to existing customers, which is potentially faster than the sell-in process for new clients.
Acquisition of GXPi underlines efforts in Life Science market
Effective at the beginning of the third quarter, Formpipe acquired UK-based GXPi, which provides compliance solutions to clients in Life Science. The firm is active in both Europe and the US, and features several of the leading multinationals in the sectors as its clients.
Formpipe Software mentions in their report that they had evaluated acquisition opportunities regarding this market segment for a while, and identifies several key benefit areas. The perceived key benefits lie in the takeover of an established sales force and years of product and delivery experience in the Life Science, as well as new cross-sales opportunities, both for Formpipe’s Platina QMS as well as GXPi’s cloud-based QMS solutions for small and medium sized client firms.
We see it as positive that the founder and CEO of GXPi will lead the new merged Life Science business area within Formpipe, and as it seems also the remaining leadership of GXPi remains in the company.
Focus of Swedish authorities should be back to normal after double elections, while Danish municipalities remain a challenging market
GXPi acquisition could be a key lever for entering the Life Science market successfully
In addition, the acquisition has been structured with a performance-based component, allowing for a further maximum 3,5 million GBP purchase price calculated as a 50% share of the EBITDA contribution over 3 years of the new combined Life Science team.
Compared to the 1,3 million GBP initial purchase price (of which around 50% was paid in cash and the other half in newly issued shares), this is a quite heavy performance incentive for the new business area, which we see as a catalyst for the market traction of Formpipe’s Life Science solutions going forward.
Financial position
Total interest-bearing debt was further reduced to 147 MSEK (166 MSEK) while net debt was at 140 MSEK (160 MSEK). The reduction of net debt after the major acquisition in 2012 therefore seems to have slowed down somewhat. This was however partly due to the financing of the GXPi acquisition without raising any additional financing, which shows the ongoing commitment of Formpipe to the reduction of their debt position. In addition, some of the reduction in amortization is a pure accounting effect, due to exchange rate differences as part of the debt is denoted in Danish crowns.
Formpipe’s net debt reduction slowed down, but the GXPi acquisition was done without additional external financing
Financial forecasts
After the second quarter had been in line with the previous year’s
development, also the third quarter followed historical patterns, showing a slower sales growth after adjusting for the GXPi acquisition. The
expectations for the upcoming fourth quarter are therefore as usual higher, since this is seasonally the best performing time in the financial year. We have adjusted our expectations higher to include the revenue contribution of GXPi. It is however unclear whether sales patterns in the life science sector follow the seasonality of the rest of Formpipe’s business, and we will follow the future developments in this regard.
The signing of a major contract with the city of Stockholm is now further delayed, after a competitor had requested a review of the contract allocation process, which is not unusual in the industry. Unfortunately, the allocation process has been declared as uncompliant in the first instance, but both the city of Stockholm and Formpipe have used their right to oppose this decision. During the next weeks, a decision will be made whether this opposition is approved. In that case, a potential following review of the case in the next court instance could take several months, so that a potential positive outcome of the case probably can be expected by Q2 2015.
Formpipe’s business model builds on a combination of recurring license as well as support and maintenance revenues, which the client either pays as part of a SaaS (Software as a Service) licensing model or in addition to a delivery fee for initial implementation of the software. How clients choose to negotiate the model for the recurring fees has a significant impact on Formpipe’s license revenues and margins in individual quarters, but makes no major difference in the long run. The trend, in accordance with the overall software industry, goes towards more clients opting for a SaaS model, similar to hiring a solution. The analysis below focuses on the steady growth of support and maintenance revenues, which is a critical driver for long-term profitability in the firm. Around 50% of revenues are now recurring, which is a big stability factor for the firm.
Seasonally weak third quarter and bigger expectations for Q4 – although signing of major contract with Stockholm city is delayed further
A high share of recurring revenues contributes to a strong cash flow and lowers the company’s risk profile
No major adjustments have been made to our estimates for 2014, apart from the inclusion of GXPi, which we expect to have a positive EBIT contribution from around the second half of 2015.
Valuation
Since the acquisition of GXPi, mainly due to its size and the chosen
performance-based purchase pricing, had no major long-term effect on the debt and risk profile of Formpipe, our WACC remains at 11 percent. We calculate with an average growth of 4,8 percent between 2016 and 2023 and an EBIT margin of 15 percent. The resulting motivated value per share is 8.7 (9) SEK.
Bull case
In a bull scenario, both the long-term archiving and Life Science
propositions will get traction in the market under 2015 and contribute to sales and profit above current expectations. The overall market conditions for the firm increase somewhat and all in all, revenues therefore increase quicker at an average rate of 7,5% while long-term average EBIT margin would be at 20%. This results in a motivated value of 15 SEK.
Bear case
In our bear case, neither the long-term archiving nor the Life Science solutions get significant traction in the market. The overall market remains somewhat on hold, meaning that sales growth and resource utilization for Formpipe Software will be slower as a result. All in all, revenues would increase at an average 4% and long-term average EBIT margin would lie at 11%. The resulting motivated value is 4 SEK.
Stock and owner information
Median turnover in Formpipe’s stock during the last 12 months was at around 146 000 shares per day. A key weakness in the firm today is in our opinion the lack of a strong major shareholder, the addition of which would be beneficial for Formpipe in the future. We have not seen any major changes in the shareholder structure since our last update after Q1 2014.
Actuals & Forecasts
(SEKm) 2013 Q1'14 Q2'14 Q3'14 Q4'14E 2014E Q1'15E Q2'15E Q3'15E Q4'15E 2015E
Sales 294 79 84 82 102 347 92 94 85 105 376
EBITDA 65 15 16 17 23 71 22 23 19 25 89
EBIT 27 5 6 5 13 30 11 12 8 14 45
PTP 20 3 4 3 11 22 9 10 6 12 37
EPS (SEK) 0.32 0.06 0.06 0.04 0.17 0.33 0.14 0.16 0.08 0.19 0.57
Sales growth YoY 46% 18% 16% 16% 21% 18% 16% 12% 4% 3% 8%
EBIT margin 9.3% 6.7% 7.1% 6.5% 12.8% 8.6% 12.0% 13.0% 8.8% 13.7% 12.0%
EPS growth YoY 15% 609% 56% -60% -3% 1% 147% 160% 108% 12% 75%
Source: Redeye research
Our DCF valuation motivates a value of 8.7 SEK per share
The bull scenario value is 15 SEK per share
A bear case development indicates a value of 4 SEK per share
Formpipe still misses a strong major shareholder, which we see as a long run disadvantage
Investment Case - Formpipe
Formpipe’s solutions help its clients to manage an ever increasing flow of information, which is a strong underlying driver for the business. The firm has a stable customer base which primarily consists of public sector actors in Sweden and Denmark, with a strong base of recurring revenues which creates stability in the business. Growth opportunities exist both in existing as well as new markets, such as the Life Science sector.
Formpipe has several organic and acquisition-based growth opportunities. Cross-selling can be realized by bringing solutions from the Swedish to the Danish market and vice versa, which is a result of the Traen acquisition in 2012. We expect such cross-selling to contribute positively to growth during 2015. In addition, Formpipe has created an offer targeted at the Life Science sector called Platina QMS (quality management system), which can be a future growth driver for the firm. The Life Science industry shares many parallels with the public sector as it is highly regulated by rules and regulations, not least from the US FDA (Food and Drug Administration). Life Science is however a highly globalized market, which could be of importance for Formpipe since current public sector solutions are rather customized to individual geographic markets. We see Formpipe's acquisition of UK-based GXPi, a provider of compliance management solutions to the Life Science sector, as a confirmation for this, since the UK is one of the hubs for Life Science within Europe and globally.
Another product-based opportunity is Formpipe's solution for long-term archiving, where Formpipe is continuing to carry this solution it developed out to the market. While the benefit proposition for customers is strong, the market seems to take its time to adapt such solutions. As a result, we expect this area to gain traction earliest during 2015.
The current stock valuation has not priced in a full successful
commercialization of both key growth opportunities described. After a slowing market 2013, Formpipe exceeded our revenue expectations for most of 2014. At the same time, profitability was put under pressure due to growth-related costs, which impacted the stock development. For 2015, we however continue to see Formpipe as a strong player in a stable market, with two opportunities for additional growth in the Life Science and long-term archive propositions. If any one of these gain significant traction in the market, a strong revaluation of the stock might be possible.
Key risks in the stock are mainly related to the level of debt, a result of the acquisition in Denmark 2012, in addition to increased competition both from local players as well as international firms. Another risk is that the public sector might face reduced budgets over time and therefore might have less economic freedom to invest in systems such as Formpipe’s.
Formpipe helps to manage an ever increasing flow of information
The company has several key growth opportunities which have not yet gotten full market traction
Formpipe’s two key growth opportunities have not been priced in yet
Stable cash flows reduce risks, but the market competition is a risk
Summary Redeye Rating
The rating consists of five valuation keys, each constituting an overall assessment of several factors that are rated on a scale of 0 to 2 points. The maximum score for a valuation key is 10 points.
Rating changes in the report
No changes to Redeye Rating
Management 7.0p Formpipe Software's CEO Christian Sundin has a long experience from
the IT sector, has worked with Formpipe since 2006 and is
knowledgeable about the market. The company has no specific financial goals, which would be positive to have. Management shows however a high ambition level for the firm by using both product development and acquisitions to get into new markets. The acquisition of Traen and the following equity issue however still surprised many stockholders and could have been announced through clearer communication by the company.
Ownership 4.0p
The ownership rating for Formpipe Software is relatively weak since the company currently misses an active major shareholder, which we see as a disadvantage. On the positive side, CEO Christian Sundin, CFO Joakim Alfredson as well as Head of Sales & Marketing Erik Lindberg all have relatively high holdings in the firm's stock. The company also has a number of institutions among its major shareholders, which is positive. Growth prospect 6.0p Formpipe Software's market seems stable with underlying growth.
Customers are mainly from the public sector and a big part of revenues are recurring, which creates stability in the business model. We see good growth possibilities since the company has both cross-sales opportunities between its Danish and Swedish operations after the Traen acquisition. In addition, new solutions for long-term archiving and the Life Science sector are being established in the market, but have not seen their breakthrough yet.
Profitability 6.0p
Formpipe's profitability has been relatively stable apart from some quarters. Recurring revenues are increasing, mainly due an increase of sales through a SaaS-model (Software as a Service). This in turn can influence profitability in individual quarters quite heavily since license revenues temporarily could be lower, which has a big impact on the net margin. In the long run, we see this however as being positive for the firm's profitability.
Financial strength 4.0p
Before the acquisition of Traen, Formpipe Software had negative net debt. Due to the acquisition, the capital strength rating has however decreased since the debt level increased. Since the company has a clear amortization plan, we expect to increase the rating over time as the debt level decreases.
Income statement 2012 2013 2014E 2015E 2016E
Net sales 201 294 347 376 397
Total operating costs -150 -230 -276 -287 -285
EBITDA 51 65 71 89 112 Depreciation -22 -37 -41 -44 -53 Amortization 0 0 0 0 0 Impairment charges 0 0 0 0 0 EBIT 29 27 30 45 60 Share in profits 0 0 0 0 0
Net financial items -13 -8 -8 -8 -6
Exchange rate dif. 0 0 0 0 0
Pre-tax profit 16 20 22 37 54
Tax -2 -3 -5 -9 -12
Net earnings 14 16 16 29 42
Balance 2012 2013 2014E 2015E 2016E Assets
Current assets
Cash in banks 4 20 10 15 20
Receivables 103 90 107 124 139
Inventories 0 0 0 0 0
Other current assets 0 0 0 0 0
Current assets 107 110 118 139 159 Fixed assets Tangible assets 3 3 3 4 4 Associated comp. 0 0 0 0 0 Investments 0 1 1 1 1 Goodwill 438 449 497 497 497
Cap. exp. for dev. 0 0 0 0 0
O intangible rights 0 0 0 0 0
O non-current assets 27 28 0 0 0
Total fixed assets 468 482 501 502 502
Deferred tax assets 0 0 30 30 30
Total (assets) 575 592 650 671 691 Liabilities Current liabilities Short-term debt 17 15 17 15 13 Accounts payable 137 154 173 188 199 O current liabilities 0 0 0 0 0 Current liabilities 154 168 190 203 212 Long-term debt 179 157 176 159 135 O long-term liabilities 0 0 0 0 0 Convertibles 0 0 0 0 0 Total Liabilities 333 325 366 363 347
Deferred tax liab 0 0 0 0 0
Provisions 0 0 0 0 0
Shareholders' equity 242 267 283 308 345
Minority interest (BS) 0 0 0 0 0
Minority & equity 242 267 283 308 345 Total liab & SE 575 592 650 671 691 Free cash flow 2012 2013 2014E 2015E 2016E
Net sales 201 294 347 376 397 Total operating costs -150 -230 -276 -287 -285 Depreciations total -22 -37 -41 -44 -53 EBIT 29 27 30 45 60 Taxes on EBIT -4 -4 -7 -10 -13 NOPLAT 24 23 23 35 46 Depreciation 22 37 41 44 53
Gross cash flow 47 60 64 79 99
Change in WC 12 29 2 -2 -4
Gross CAPEX -336 -51 -61 -44 -53
Free cash flow -278 39 6 32 42
Capital structure 2012 2013 2014E 2015E 2016E
Equity ratio 42% 45% 44% 46% 50% Debt/equity ratio 81% 64% 68% 57% 43% Net debt 192 151 183 160 128 Capital employed 434 418 466 468 473 Capital turnover rate 0.4 0.5 0.5 0.6 0.6
Growth 2012 2013 2014E 2015E 2016E
Sales growth 79% 46% 18% 8% 6%
EPS growth (adj) -77% 15% 1% 75% 46%
Profitability 2012 2013 2014E 2015E 2016E
ROE 7% 6% 6% 10% 13% ROCE 10% 6% 6% 9% 12% ROIC 19% 5% 6% 7% 10% EBITDA margin 25% 22% 21% 24% 28% EBIT margin 14% 9% 9% 12% 15% Net margin 7% 5% 5% 8% 11%
Data per share 2012 2013 2014E 2015E 2016E
EPS 0.28 0.32 0.33 0.57 0.83
EPS adj 0.28 0.32 0.33 0.57 0.83
Dividend 0.00 0.00 0.07 0.11 0.17
Net debt 3.92 3.09 3.64 3.18 2.55
Total shares 48.94 48.93 50.14 50.14 50.14
Valuation 2012 2013 2014E 2015E 2016E
EV 192.0 430.2 448.4 425.4 393.8 P/E 0.0 17.7 16.3 9.3 6.4 P/E diluted 0.0 17.7 16.3 9.3 6.4 P/Sales 0.0 0.9 0.8 0.7 0.7 EV/Sales 1.0 1.5 1.3 1.1 1.0 EV/EBITDA 3.8 6.7 6.3 4.8 3.5 EV/EBIT 6.7 15.8 15.1 9.4 6.6 P/BV 0.0 1.0 0.9 0.9 0.8 Share information Reuters code
List Small Cap
Share price 5.3
Total shares, million 50.1
Market Cap, MSEK 265.8
Management & board
CEO Christian Sundin
CFO Joakim Alfredson
IR
Chairman Bo Nordlander
Financial information
FY 2014 Results February 10, 2015
Analysts Redeye AB
Alexander Sattelmaier Mäster Samuelsgatan 42, 10tr [email protected] 111 57 Stockholm
DCF valuation Cash flow, MSEK
WACC (%) 10.9 % NPV FCF (2013-2015) 37
NPV FCF (2016-2022) 221
NPV FCF (2023-) 329
Non-operating assets 20
Interest-bearing debt -172 Fair value estimate MSEK 436 Assumptions 2015-2021 (%)
Average sales growth 4.3 % Fair value e. per share, SEK 8.7
EBIT margin 15.0 % Share price, SEK 5.3
Share performance Growth/year 12/14e
1 month -13.1 % Net sales 31.3 %
3 month -15.2 % Operating profit adj 1.8 %
12 month -8.6 % EPS, just 7.9 %
Since start of the year -4.5 % Equity 8.2 %
Shareholder structure % Capital Votes
Avanza Pension Försäkring AB 9.3 % 9.3 %
Swedbank Robur fonder 6.1 % 6.1 %
SHB fonder 5.6 % 5.6 % Nordnet Pensionsförsäkring AB 4.7 % 4.7 % SEB fonder 4.6 % 4.6 % Andra AP-fonden 4.2 % 4.2 % Humle fonder 4.0 % 4.0 % Wallinder & Co AB 2.7 % 2.7 % Wernhoff Thomas 1.7 % 1.7 % Lindeberg Erik 1.5 % 1.5 %
Revenue & Growth (%) EBIT (adjusted) & Margin (%)
Earnings per share Equity & debt-equity ratio (%)
Sales division Geographical areas
Conflict of interests Company description
Alexander Sattelmaier owns shares in the company : No
Redeye performs/have performed services for the Company and receives/have received compensation from the Company in connection with this.
Since its start in 2004, Formpipe showed strong growth and increasing margins. The firm's main sales focus is in the public sector, reducing sensitivity to economic cycles. Recently, an additional focus on selected private market actors has been added with the Life Science segment. Increasing recurring revenues from support and maintenance make Formpipe's business model attractive.
0,0% 10,0% 20,0% 30,0% 40,0% 50,0% 60,0% 70,0% 80,0% 90,0% 0 50 100 150 200 250 300 350 400 450
2011 2012 2013 2014E 2015E 2016E Net sales Net sales growth
0,0% 2,0% 4,0% 6,0% 8,0% 10,0% 12,0% 14,0% 16,0% 18,0% 20,0% 0 10 20 30 40 50 60 70
2011 2012 2013 2014E 2015E 2016E EBIT adj EBIT margin
0 0,2 0,4 0,6 0,8 1 1,2 1,4 0 0,2 0,4 0,6 0,8 1 1,2 1,4
2011 2012 2013 2014E 2015E 2016E EPS, unadjusted EPS, adjusted
0,0% 10,0% 20,0% 30,0% 40,0% 50,0% 60,0% 70,0% 80,0% 90,0% 0 0,1 0,2 0,3 0,4 0,5 0,6 0,7
2011 2012 2013 2014E 2015E 2016E Equity ratio Debt-equity ratio
DISCLAIMER
Important information
Redeye AB ("Redeye" or "the Company") is a specialist investment banking boutique that focuses on small and mid-cap growth companies in the Nordic region. We focus on the IT, life sciences, media, betting, clean tech and commodities sectors. We provide services within Corporate Broking, Corporate Finance, equity research, investor relations and media services. Our strengths are our award-winning research and analysis department, experienced advisers, a unique investor network, and powerful distribution channel redeye.se. Redeye was founded in 1999 and since 2007 has been subject to the supervision of the Swedish Financial Supervisory Authority.
Redeye is licensed to; receive and transmit orders in financial instruments, provide investment advice to clients regarding financial instruments, prepare and disseminate financial analyses/recommendations for trading in financial instruments, execute orders in financial instruments on behalf of clients, place financial instruments without position taking, provide for the safekeeping of financial instruments, accept funds with accounting responsibility, provide corporate advice and services within mergers and acquisition, provide services in conjunction with the provision of guarantees regarding financial instruments and to operate as a Certified Advisory business (ancillary authorization).
Limitation of liability
This document was prepared for information purposes for general distribution and is not intended to be advisory. The information contained in this analysis is based on sources deemed reliable by Redeye. However, Redeye cannot guarantee the accuracy of the information. The forward-looking information in the analysis is based on subjective assessments about the future, which constitutes a factor of uncertainty. Redeye cannot guarantee that forecasts and forward-looking statements will materialize. Investors take all investment decisions independently. This analysis is intended to be one of a number of tools that can be used in making an investment decision. All investors are therefore encouraged to supplement this information with additional relevant data and to consult a financial advisor prior to an investment decision. Accordingly, Redeye accepts no liability for any loss or damage resulting from the use of this analysis.
Potential conflict of interest
Redeye’s research department is regulated by organisational and administrative rules established to avoid conflicts of interest and to ensure the objectivity and independence of its analysts. The following applies:
For companies that are the subject of Redeye’s research analysis, the applicable rules include those established by the Swedish Financial Supervisory Authority pertaining to investment recommendations and the handling of conflicts of interest. Furthermore, Redeye employees are not allowed to trade in financial instruments of the company in question, effective from the day that the decision is taken to produce a research analysis on the company and the two banking days after the report is published.
An analyst may not engage in corporate finance transactions without the express approval of management, and may not receive any remuneration directly linked to such transactions.
Redeye may carry out an analysis upon commission or in exchange for payment from the company that is the subject of the analysis, or from an underwriting institution in conjunction with a merger and acquisition (M&A) deal, new share issue or a public listing. Readers of these reports should assume that Redeye may have received or will receive remuneration from the company/companies cited in the report for the performance of financial advisory services. Such remuneration is of a predetermined amount and is not dependent on the content of the analysis.
Redeye’s research coverage
Redeye’s research analyses consist of case-based analyses, which implies that the frequency of the analytical reports may vary over time. Unless otherwise expressly stated in the report, the analysis is updated when considered necessary by the research department, for example in the event of significant changes in market conditions or events related to the issuer/the financial instrument.
Recommendation structure
Redeye does not issue any investment recommendations for fundamental analysis. However, Redeye has developed a proprietary analysis and rating model, Redeye Rating, in which each company is analysed and evaluated. This analysis aims to provide an independent assessment of the company in question, its opportunities, risks, etc. The purpose is to provide an objective and professional set of data for owners and investors to use in their decision-making.
Redeye’s recommendations for technical analyses are: Buy (Köp) and Sell (Sälj). The investment horizon for these recommendations is very short, at usually less than 1 month.
Redeye Rating (2014-06-10)
Rating Management Ownership Growth
Prospect Profitability Financial Strength
7,5p - 10,0p 22 28 11 4 16
3,5p - 7,0p 43 32 54 30 26
0,0p - 3,0p 1 6 1 32 24
Company N 66 66 66 66 66
Duplication and distribution
This document may not be duplicated, reproduced or copied for purposes other than personal use. The document may not be distributed to physical or legal entities that are citizens of or domiciled in any country in which such distribution is prohibited according to applicable laws or other regulations.
